| Schedule of Segment Reported Segment Revenues, and Significant Segment Expenses |
The following table presents information about reported segment revenues, and significant segment expenses as provided to the CODM (in thousands). Certain prior period segment expense amounts have been recast to reflect the current year presentation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue, net |
|
$ |
14,285 |
|
|
$ |
11,786 |
|
|
$ |
28,029 |
|
|
$ |
23,090 |
|
Total revenue |
|
|
14,285 |
|
|
|
11,786 |
|
|
|
28,029 |
|
|
|
23,090 |
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenue |
|
|
1,273 |
|
|
|
685 |
|
|
|
2,305 |
|
|
|
1,519 |
|
Direct, external research and development expenses by program: |
|
|
|
|
|
|
|
|
|
|
|
|
Pemivibart(1) |
|
|
265 |
|
|
|
906 |
|
|
|
453 |
|
|
|
2,297 |
|
VYD2311(2) |
|
|
20,350 |
|
|
|
1,011 |
|
|
|
43,153 |
|
|
|
2,513 |
|
VBY329(3) |
|
|
80 |
|
|
|
41 |
|
|
|
244 |
|
|
|
83 |
|
VMS063(4) |
|
|
182 |
|
|
|
50 |
|
|
|
311 |
|
|
|
50 |
|
Early-stage programs |
|
|
175 |
|
|
|
75 |
|
|
|
204 |
|
|
|
160 |
|
Total direct, external research and development expenses by program |
|
|
21,052 |
|
|
|
2,083 |
|
|
|
44,365 |
|
|
|
5,103 |
|
Personnel expense (research and development) |
|
|
3,532 |
|
|
|
2,743 |
|
|
|
6,699 |
|
|
|
5,923 |
|
Stock-based compensation (research and development) |
|
|
741 |
|
|
|
787 |
|
|
|
1,474 |
|
|
|
1,618 |
|
Other research and development expense |
|
|
4,042 |
|
|
|
3,960 |
|
|
|
7,560 |
|
|
|
7,570 |
|
Total research and development expense |
|
|
29,367 |
|
|
|
9,573 |
|
|
|
60,098 |
|
|
|
20,214 |
|
Selling, general and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing costs |
|
|
6,961 |
|
|
|
3,341 |
|
|
|
12,179 |
|
|
|
6,301 |
|
Personnel expense (selling, general and administrative) |
|
|
9,847 |
|
|
|
5,230 |
|
|
|
17,535 |
|
|
|
10,720 |
|
Stock-based compensation (selling, general and administrative) |
|
|
2,154 |
|
|
|
2,393 |
|
|
|
4,118 |
|
|
|
4,388 |
|
Other selling, general and administrative expense |
|
|
10,503 |
|
|
|
5,624 |
|
|
|
20,750 |
|
|
|
11,930 |
|
Total selling, general and administrative expense |
|
|
29,465 |
|
|
|
16,588 |
|
|
|
54,582 |
|
|
|
33,339 |
|
Total operating costs and expenses |
|
|
60,105 |
|
|
|
26,846 |
|
|
|
116,985 |
|
|
|
55,072 |
|
Loss from operations |
|
|
(45,820 |
) |
|
|
(15,060 |
) |
|
|
(88,956 |
) |
|
|
(31,982 |
) |
Other income: |
|
|
|
|
|
|
|
|
|
|
|
|
Other income, net(5) |
|
|
1,427 |
|
|
|
400 |
|
|
|
3,163 |
|
|
|
1,033 |
|
Total other income, net |
|
|
1,427 |
|
|
|
400 |
|
|
|
3,163 |
|
|
|
1,033 |
|
Net loss |
|
$ |
(44,393 |
) |
|
$ |
(14,660 |
) |
|
$ |
(85,793 |
) |
|
$ |
(30,949 |
) |
(1)In March 2023, the Company announced the nomination of VYD222 (pemivibart) as a novel mAb therapeutic option for COVID-19. (2)In March 2024, the Company announced the nomination of VYD2311 as a novel mAb therapeutic option for COVID-19. (3)In November 2025, the Company announced the nomination of VBY329 as an RSV mAb candidate for preclinical development. (4)In April 2026, the Company announced the nomination of VMS063 as a measles mAb candidate for preclinical development. (5)Includes interest income of $1,503 and $405 for the three months ended June 30, 2026 and 2025, respectively, and interest income of $3,246 and $1,033 for the six months ended June 30, 2026 and 2025, respectively.
|